-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
VBI Vaccines (NASDAQ:VBIV) Shares Pass Below 200 Day Moving Average of $1.07
VBI Vaccines (NASDAQ:VBIV) Shares Pass Below 200 Day Moving Average of $1.07
Shares of VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.07 and traded as low as $0.70. VBI Vaccines shares last traded at $0.71, with a volume of 389,743 shares.
Analysts Set New Price Targets
Separately, Raymond James decreased their price target on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating for the company in a research note on Tuesday, August 9th.
Get VBI Vaccines alerts:VBI Vaccines Trading Down 3.2 %
The company has a market capitalization of $182.28 million, a P/E ratio of -1.81 and a beta of 1.86. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.29 and a quick ratio of 2.19. The stock's 50 day moving average is $0.91 and its 200-day moving average is $1.07.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). The business had revenue of $0.35 million during the quarter, compared to analysts' expectations of $0.70 million. VBI Vaccines had a negative return on equity of 75.37% and a negative net margin of 15,391.36%. As a group, equities research analysts anticipate that VBI Vaccines Inc. will post -0.37 earnings per share for the current year.Institutional Investors Weigh In On VBI Vaccines
A number of hedge funds and other institutional investors have recently bought and sold shares of VBIV. State Street Corp grew its holdings in VBI Vaccines by 31.1% in the first quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after purchasing an additional 3,844,698 shares during the period. Millennium Management LLC grew its holdings in VBI Vaccines by 211.7% in the second quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after purchasing an additional 1,209,393 shares during the period. Renaissance Technologies LLC grew its holdings in shares of VBI Vaccines by 358.7% during the second quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock valued at $638,000 after buying an additional 617,400 shares during the last quarter. Frontier Wealth Management LLC grew its holdings in shares of VBI Vaccines by 1,571.7% during the first quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock valued at $951,000 after buying an additional 565,800 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of VBI Vaccines by 88.9% during the first quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock valued at $1,343,000 after buying an additional 380,839 shares during the last quarter. Hedge funds and other institutional investors own 39.96% of the company's stock.
About VBI Vaccines
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
Featured Stories
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.07 and traded as low as $0.70. VBI Vaccines shares last traded at $0.71, with a volume of 389,743 shares.
VBI疫苗公司(納斯達克代碼：VBIV-GET評級)的股價在週五的交易中跌破200日移動均線。該股的200日移動均線切入位為1.07美元，交易價格低至0.70美元。VBI疫苗公司的股票最新報0.71美元，成交量為389,743股。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, Raymond James decreased their price target on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating for the company in a research note on Tuesday, August 9th.
另外，雷蒙德·詹姆斯將VBI疫苗的目標股價從6.00美元下調至5.00美元，並在8月9日(星期二)的一份研究報告中為該公司設定了“強力買入”評級。
VBI Vaccines Trading Down 3.2 %
VBI疫苗價格下跌3.2%
The company has a market capitalization of $182.28 million, a P/E ratio of -1.81 and a beta of 1.86. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.29 and a quick ratio of 2.19. The stock's 50 day moving average is $0.91 and its 200-day moving average is $1.07.
該公司市值為1.8228億美元，市盈率為-1.81，貝塔係數為1.86。該公司的債務權益比為0.20，流動比率為2.29，速動比率為2.19。該股的50日移動均線切入位在0.91美元，200日移動均線切入位在1.07美元。
Institutional Investors Weigh In On VBI Vaccines
機構投資者參與VBI疫苗
A number of hedge funds and other institutional investors have recently bought and sold shares of VBIV. State Street Corp grew its holdings in VBI Vaccines by 31.1% in the first quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after purchasing an additional 3,844,698 shares during the period. Millennium Management LLC grew its holdings in VBI Vaccines by 211.7% in the second quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after purchasing an additional 1,209,393 shares during the period. Renaissance Technologies LLC grew its holdings in shares of VBI Vaccines by 358.7% during the second quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock valued at $638,000 after buying an additional 617,400 shares during the last quarter. Frontier Wealth Management LLC grew its holdings in shares of VBI Vaccines by 1,571.7% during the first quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock valued at $951,000 after buying an additional 565,800 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of VBI Vaccines by 88.9% during the first quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock valued at $1,343,000 after buying an additional 380,839 shares during the last quarter. Hedge funds and other institutional investors own 39.96% of the company's stock.
一些對衝基金和其他機構投資者最近買賣了VBIV的股票。道富集團第一季度持有的VBI疫苗增加了31.1%。道富集團目前持有這家生物製藥公司16,216,811股股票，價值26,920,000美元，在此期間又購買了3,844,698股。千禧管理有限責任公司在第二季度增持了VBI疫苗211.7%。Millennium Management LLC現在擁有這家生物製藥公司1,780,752股股票，價值1，44萬美元，在此期間又購買了1,209,393股。復興科技有限責任公司在第二季度增持了358.7%的VBI疫苗股票。復興科技有限責任公司現在擁有這家生物製藥公司78.95萬股票，價值63.8萬美元，在上個季度又購買了61.74萬股票。FronTier Wealth Management LLC在第一季度增持了VBI疫苗股票1,571.7%。FronTier Wealth Management LLC現在擁有601,800股這家生物製藥公司的股票，價值951,000美元，此前在上個季度又購買了565,800股。最後，美國銀行DE在第一季度增持了VBI疫苗公司的股票88.9%。美國銀行DE目前持有809,425股這家生物製藥公司的股票，價值1,343,000美元，此前在上一季度又購買了380,839股。對衝基金和其他機構投資者持有該公司39.96%的股票。
About VBI Vaccines
關於VBI疫苗
(Get Rating)
(獲取評級)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
VBI疫苗公司是一家生物製藥公司，開發和銷售用於治療傳染病和免疫腫瘤學的疫苗。該公司提供一種預防性乙肝疫苗Sci-B-Vac。它還參與VBI-2601(BRII-179)的開發，VBI-2601(BRII-179)是治療慢性乙肝感染的免疫治療候選藥物。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取StockNews.com關於VBI疫苗的研究報告(VBIV)
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何？
- 利潤下降對CarMax價值主張的挑戰
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到VBI疫苗的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對VBI疫苗和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧